Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — J.P. Morgan Annual Healthcare Conference 2022
14 slides from Century Therapeutics's conference presentation, Jan 11, 2022
Slide 1: J.P. Morgan Annual Healthcare Conference January 2022
1 J.P. MORGAN ANNUAL HEALTHCARE CONFERENCE January 2022
Slide 2: Forward-Looking Statements
2 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts
Slide 3: Our mission
3 3 Our mission Century Therapeutics aims to expand patient access to life-saving cell therapies by developing innovative products that are more effective, tolerable, accessible, and affordable versus existing cells therapies. Building on a strong foundation, we believe we are poised to lead in iPSC
Slide 4: Century Therapeutics - Emerging Leader in Allogeneic Cell Therapies for Cancer
CENTURY THERAPEUTICS - EMERGING LEADER IN ALLOGENEIC CELL THERAPIES FOR CANCER COMPREHENSIVE iPSC CELL PLATFORM For immune effector cells WHOLLY OWNED PIPELINE CNTY-101: Next-gen CD19 iNK program CNTY-102: Dual targeted γδ iT program STATE-OF-THE ART GMP MANUFACTURING FACILITY In cash, cash equivale
Slide 5: Century's end-to-end platform has the key components to realize potential of iPSC
5 5 Multiple gene edits Engineered iPSC iNK cell iT cell iPSC bank Cell Engineering Manufacturing CENTURY’S END-TO-END PLATFORM HAS THE KEY COMPONENTS TO REALIZE POTENTIAL OF IPSC ITERATIVE ENHANCEMENT OF PRODUCT FITNESS AND FUNCTIONALITY Engineered iPSC MCB Differentiation CD34+ HSC T cell NK cell
Slide 6: Allo-Evasion 1.0 central to our approach to increase durability of response
6 6 ALLO-EVASIONTM 1.0 CENTRAL TO OUR APPROACH TO INCREASE DURABILITY OF RESPONSE β2M KO (HLA-I) HLA-E KI CIITA KO (HLA-II) CD8+ T Cell CD4+ T Cell NK cell • 3 core edits to prevent the 3 major pathways of host rejection • CNTY-101 expected to be the first candidate designed to evade all 3 pathways
Slide 7: Century's lead iNK and iT programs
7 7 CENTURY’S LEAD INK AND IT PROGRAMS iNK Candidates iT Candidates • CNTY-101: First candidate entering P1 ELiPSE-1 in R/R CD19+ B cell malignancies (expected in 2H22) • CNTY-103: First candidate for solid tumors (IND expected in 2023) • Multi-specific design to address heterogeneity of recurrent G
Slide 8: Century and Bristol Myers Squibb collaboration
8 8 CENTURY AND BRISTOL MYERS SQUIBB COLLABORATION • Comprehensive iPSC cell platform with CAR-iNK and CAR-iT candidates • State of the art cell engineering and manufacturing • Allo-evasion technology to potentially enable redosing and potentially increase durability of clinical responses Century Th
Slide 9: Bristol Myers Squibb collaboration financial summary
9 9 BRISTOL MYERS SQUIBB COLLABORATION FINANCIAL SUMMARY Upfront Milestones Royalties $100M $100M upfront payment Co-promotion Century eligible for additional payments for future program initiation, development, regulatory and commercial milestones Up to ~ $3B Century to receive tiered royalties on
Slide 10: Pipeline
10 10 Product iPSC Platform Targets Indications Expected IND Submission Discovery Preclinical Clinical Collaborator CNTY-101 iNK CD19 B-Cell Malignancies Mid 2022 CNTY-103 iNK CD133 + EGFR Glioblastoma 2023 CNTY-102 iT CD19 + CD79b B-Cell Malignancies 2024 CNTY-104 iNK/iT Multi- specific Acute Myelo
Slide 11: Anticipated 2022 catalysts
11 11 ANTICIPATED 2022 CATALYSTS • CNTY-101: IND submission (Mid-2022) • CNTY-101 Phase 1 (ELiPSE-1) start in B-cell malignancies (2H22) • CNTY-103: Initiate manufacturing of MCB (Mid-2022) • CNTY-103: Select development candidate, initiate IND enabling activities (4Q22) • Future pipeline candidates
Slide 12: Century Therapeutics' unique investment opportunity
12 12 CENTURY THERAPEUTICS’ UNIQUE INVESTMENT OPPORTUNITY • CNTY-101 IND submission on track for mid-2022 • Century’s most advanced allogeneic cell therapy designed to avoid 3 pathways of host rejection • CNTY-103 IND enabling activities to initiate in 2022 • Century’s first solid tumor candidate fo
Slide 13: Century Therapeutics
CENTURY THERAPEUTICS,
Slide 14: Q&A
14 14 Q&A GREG RUSSOTTI, PhD Chief Technology Officer Century Therapeutics GREG RUSSOTTI, PhD Chief Technology Officer Century Therapeutics Lalo Flores, PhD ǀ CEO Hy Levitsky, MD ǀ President R&D Michael Diem, MD, ǀ CBO
Century Therapeutics — J.P. Morgan Annual Healthcare Conference 2022 on 6ix